Literature DB >> 1349946

Population screening for fragile X.

G Turner1, H Robinson, S Laing, M van den Berk, A Colley, A Goddard, S Sherman, M Partington.   

Abstract

A screening programme to detect fragile X syndrome has been operating in New South Wales, Australia, since 1984. The aim of this programme is to find previously unidentified individuals with the syndrome so that their extended families can be properly informed of the risks before making decisions about childbearing. 14,225 individuals attending adult and child facilities for the intellectually handicapped have been screened, of whom 8172 have been offered testing for the fragile X syndrome with a 79% uptake of the service. 253 probands were found, and in the extended families 818 females at 25-100% risk of being carriers were interviewed and counselled. Continuing contact was maintained and prenatal diagnosis was offered. The effect of the programme was assessed in a subgroup of 90 individuals, most of whom were appreciative of the service and felt that they had been adequately informed. The influence of knowing the diagnosis and its genetic implications were also assessed, the main consequences being a 26% reduction in births and a 61% uptake of prenatal diagnosis. Improved techniques for diagnosis of fragile X have benefited the families identified and counselled, suggesting that systematic screening for fragile X should be an essential component of community genetic services.

Entities:  

Keywords:  Genetics and Reproduction

Mesh:

Year:  1992        PMID: 1349946     DOI: 10.1016/0140-6736(92)91142-u

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

Review 1.  The impact of FMR1 gene mutations on human reproduction and development: a systematic review.

Authors:  Vincenzo Noto; Conor Harrity; David Walsh; Kevin Marron
Journal:  J Assist Reprod Genet       Date:  2016-07-18       Impact factor: 3.412

2.  Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group.

Authors:  B B de Vries; A M van den Ouweland; S Mohkamsing; H J Duivenvoorden; E Mol; K Gelsema; M van Rijn; D J Halley; L A Sandkuijl; B A Oostra; A Tibben; M F Niermeijer
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

Review 3.  Fragile X syndrome.

Authors:  A E Donnenfeld
Journal:  Indian J Pediatr       Date:  1998 Jul-Aug       Impact factor: 1.967

Review 4.  Fragile X syndrome.

Authors:  E Wiebe; A Wiebe
Journal:  Can Fam Physician       Date:  1994-02       Impact factor: 3.275

5.  Population studies of the fragile X: a molecular approach.

Authors:  P A Jacobs; H Bullman; J Macpherson; S Youings; V Rooney; A Watson; N R Dennis
Journal:  J Med Genet       Date:  1993-06       Impact factor: 6.318

6.  DNA testing for fragile X syndrome in schools for learning difficulties.

Authors:  S F Slaney; A O Wilkie; M C Hirst; R Charlton; M McKinley; J Pointon; Z Christodoulou; S M Huson; K E Davies
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

7.  Impact of genetic counselling after neonatal screening for Duchenne muscular dystrophy.

Authors:  E Hildes; H K Jacobs; A Cameron; S S Seshia; F Booth; J A Evans; K Wrogemann; C R Greenberg
Journal:  J Med Genet       Date:  1993-08       Impact factor: 6.318

Review 8.  Blood specimens from patients referred for cytogenetic analysis: Vanderbilt University experience from 1985 to 1992.

Authors:  M G Butler; T Hamill
Journal:  South Med J       Date:  1995-03       Impact factor: 0.954

Review 9.  The fragile X syndrome.

Authors:  B B de Vries; D J Halley; B A Oostra; M F Niermeijer
Journal:  J Med Genet       Date:  1998-07       Impact factor: 6.318

Review 10.  Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development.

Authors:  Andreea S Pop; Baltazar Gomez-Mancilla; Giovanni Neri; Rob Willemsen; Fabrizio Gasparini
Journal:  Psychopharmacology (Berl)       Date:  2014-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.